Display Settings:

Format

Send to:

Choose Destination

    Lung Cancer. 2007 Jun;56(3):459-63. Epub 2007 Feb 20.

    Chemotherapy induced reversible posterior leukoencephalopathy syndrome.

    Connolly RM, Doherty CP, Beddy P, O'Byrne K.

    Academic Unit of Clinical & Molecular Oncology, Trinity College Dublin & St. James's Hospital, Dublin 8, Ireland. roisinconnolly@gmail.com

    The reversible posterior leukoencephalopathy syndrome (RPLES) is a condition characterised by reversible neurological and radiological findings that has been associated with use of immunosuppressive, chemotherapeutic and more recently novel targeted therapies. We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy. The clinical, radiological and EEG findings during and post event are presented and are in keeping with a diagnosis of RPLES. Early recognition of this rare syndrome, supportive management and withdrawal of the offending agent appear to result in a reversal of the manifestations described.

    PMID: 17316891 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read

    Patient drug information

    • Cisplatin (Platinol®-AQ)

      Your doctor has ordered the drug cisplatin to help treat your illness. The drug is given by injection into a vein.